proxyvotesnow.com

Home › Companies › Stoke Therapeutics, Inc. › 2025-2026

Stoke Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Stoke Therapeutics, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 5Ballot items
  • 227Asset managers
  • 1,407Fund votes
  • 2026-06-03Meeting date

Proxy season: 2024-2025 2025-2026

Explore Stoke Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Stoke Therapeutics, Inc.

These tallies are Stoke Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Stoke Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-03
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: G. Clare Kahn, Ph.D. 49,722,339---- 308,6445,143,930 Majority: yes
Elect Director: Adrian Krainer, Ph.D. 36,531,612---- 13,499,3715,143,930 Majority: yes
Elect Director: Julie Anne Smith 43,500,649---- 6,530,3345,143,930 Majority: yes
Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026: 55,121,1632,03651,714 ---- Majority: yes
Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026: 36,436,27513,565,29329,415 --5,143,930 Majority: yes

Source: Stoke Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.

How asset managers voted at the Stoke Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 227 asset managers that disclosed a Stoke Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST 27%
FOR: 36,436,275AGAINST: 13,565,293

Stoke Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Co”): 36,436,275 for, 13,565,293 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,240,347 outstanding shares: 59% for, 22% against (80% of the company cast a for/against vote).

The 225 asset managers below cast 68% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 68%AGAINST 32%
FOR: 68.2%AGAINST: 31.7%ABSTAIN: 0.2%NOT VOTED: 0.0%
Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,131,5909,998,096 00Against
RTW INVESTMENTS, LP5,623,5250 00For
Vanguard4,860,7131,500 00For
Lynx1 Capital Management LP4,109,3250 00For
Redmile Group, LLC4,077,8200 00For
T. Rowe Price3,301,017431,975 00For
BlackRock3,361,05814,642 00For
BVF INC/IL2,547,5570 00For
Wellington2,467,7140 00For
Polar Capital Holdings Plc02,142,374 00Against
Siren, L.L.C.1,995,3470 00For
State Street3,7771,863,749 00Against
DEERFIELD MANAGEMENT COMPANY, L.P.1,823,5000 00For
GEODE CAPITAL MANAGEMENT, LLC1,291,2820 00For
Charles Schwab874,7530 00For
Invesco0716,443 00Against
Candriam S.C.A.0502,020 00Against
EcoR1 Capital, LLC425,0000 00For
BAKER BROS. ADVISORS LP407,9740 00For
Erste Asset Management GmbH0396,000 00Against
BAILLIE GIFFORD & CO LTD390,8990 00For
Janus Henderson0316,254 00Against
Dimensional0305,578 00Against
MPM BioImpact LLC282,1440 00For
Northern Trust0278,625 00Against

Showing the 25 largest of 225 asset managers. See all 225 in the interactive database.

2. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 55,121,163AGAINST: 2,036

Stoke Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”): 55,121,163 for, 2,036 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,240,347 outstanding shares: 89% for, 0.1% against (89% of the company cast a for/against vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (16,889,708 for, 0 against).

FOR 99.9%
FOR: 16,889,708 (100.0%)ABSTAIN: 1,676 (0.0%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,809,4050 00For
Vanguard4,441,8540 00For
BlackRock1,638,7760 00For
T. Rowe Price1,514,4470 00For
State Street1,022,0220 00For
Charles Schwab437,3640 00For
Erste Asset Management GmbH396,0000 00For
Dimensional208,3140 00For
Equitable113,9780 00For
Victory Capital107,3600 00For
TIAA102,5640 00For
Hartford87,7450 00For
HUSSMAN INVESTMENT TRUST82,0000 00For
Lincoln Financial69,1900 00For
QUANTITATIVE MASTER SERIES LLC67,9040 00For
Principal Exchange-Traded Funds61,1050 00For
ALPS ETF Trust46,4980 00For
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares36,4470 00For
Brighthouse29,7240 1,6760For
Goldman Sachs31,3790 00For
Northern Trust31,1530 00For
Jackson National31,1290 00For
Transamerica29,0100 00For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

3. Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Adrian Krainer, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD 27%
FOR: 36,531,612WITHHELD: 13,499,371

Stoke Therapeutics, Inc.’s own tally for this item (“Elect Director: Adrian Krainer, Ph.D.”): 36,531,612 for, 13,499,371 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,240,347 outstanding shares: 59% for, 22% withheld (80% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (8,901,787 for, 0 against).

FOR 53.0%ABSTAIN 47.0%
FOR: 8,901,787 (53.0%)ABSTAIN: 7,907,597 (47.0%)
Largest asset managers voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,113,5230 4,695,8820Abstain
Vanguard4,439,8030 2,0500For
BlackRock00 1,638,7760Abstain
T. Rowe Price1,366,2530 148,1940For
State Street1,020,8230 1,1990For
Charles Schwab437,3640 00For
Erste Asset Management GmbH00 396,0000Abstain
Dimensional00 208,3140Abstain
Equitable7,7920 106,1860Abstain
Victory Capital1,0200 106,3400Abstain
TIAA102,5640 00For
Hartford87,7450 00For
Lincoln Financial37,1890 32,0010For
QUANTITATIVE MASTER SERIES LLC00 67,9040Abstain
Principal Exchange-Traded Funds00 61,1050Abstain
ALPS ETF Trust00 46,4980Abstain
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares00 36,4470Abstain
Brighthouse26,8010 4,5990For
Goldman Sachs6,3260 25,0530Abstain
Northern Trust00 31,1530Abstain
Jackson National00 31,1290Abstain
Transamerica29,0100 00For
Global X27,7060 00For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

4. Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: G. Clare Kahn, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 49,722,339WITHHELD: 308,644

Stoke Therapeutics, Inc.’s own tally for this item (“Elect Director: G. Clare Kahn, Ph.D.”): 49,722,339 for, 308,644 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,240,347 outstanding shares: 80% for, 0.5% withheld (80% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (16,659,513 for, 0 against).

FOR 99.1%
FOR: 16,659,513 (99.1%)ABSTAIN: 149,871 (0.9%)
Largest asset managers voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,809,4050 00For
Vanguard4,441,8530 10For
BlackRock1,638,7760 00For
T. Rowe Price1,366,2530 148,1940For
State Street1,022,0220 00For
Charles Schwab437,3640 00For
Erste Asset Management GmbH396,0000 00For
Dimensional208,3140 00For
Equitable113,9780 00For
Victory Capital107,3600 00For
TIAA102,5640 00For
Hartford87,7450 00For
Lincoln Financial69,1900 00For
QUANTITATIVE MASTER SERIES LLC67,9040 00For
Principal Exchange-Traded Funds61,1050 00For
ALPS ETF Trust46,4980 00For
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares36,4470 00For
Brighthouse29,7240 1,6760For
Goldman Sachs31,3790 00For
Northern Trust31,1530 00For
Jackson National31,1290 00For
Transamerica29,0100 00For
Global X27,7060 00For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

5. Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne Smith

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%
FOR: 43,500,649WITHHELD: 6,530,334

Stoke Therapeutics, Inc.’s own tally for this item (“Elect Director: Julie Anne Smith”): 43,500,649 for, 6,530,334 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,240,347 outstanding shares: 70% for, 10% withheld (80% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (11,867,689 for, 0 against).

FOR 71%ABSTAIN 29%
FOR: 11,867,689 (70.6%)ABSTAIN: 4,941,695 (29.4%)
Largest asset managers voting on “Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor ” at Stoke Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,131,5900 4,677,8150Abstain
Vanguard4,441,8420 120For
BlackRock1,638,7760 00For
T. Rowe Price1,514,4470 00For
State Street1,022,0220 00For
Charles Schwab437,3640 00For
Erste Asset Management GmbH396,0000 00For
Dimensional00 208,3140Abstain
Equitable86,1580 27,8200For
Victory Capital107,3600 00For
TIAA102,5640 00For
Hartford87,7450 00For
Lincoln Financial66,1230 3,0670For
QUANTITATIVE MASTER SERIES LLC67,9040 00For
Principal Exchange-Traded Funds61,1050 00For
ALPS ETF Trust46,4980 00For
JPMorgan44,6130 00For
Putnam40,7360 00For
ProShares36,4470 00For
Brighthouse29,7240 1,6760For
Goldman Sachs31,3790 00For
Northern Trust31,1530 00For
Jackson National18,6000 12,5290For
Transamerica29,0100 00For
Global X27,7060 00For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Largest Stoke Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Stoke Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 62,240,347 shares outstanding at the time of that meeting.

Top Stoke Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 17.88%
2RTW INVESTMENTS, LP 9.04%
3Vanguard 7.81%
4Lynx1 Capital Management LP 6.60%
5Redmile Group, LLC 6.55%
6T. Rowe Price 6.00%
7BlackRock 5.42%
8BVF INC/IL 4.09%
9Wellington 3.96%
10Polar Capital Holdings Plc 3.44%

Reported Stoke Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Stoke Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
RTW Investments, LP 9.55% 13G
Entities affiliated with FMR LLC 9.00% DEF14A
BlackRock 8.65% 13F
FMR (Fidelity) 8.65% 13F
Entities affiliated with RTW Investments, L.P. 8.53% DEF14A
Entities affiliated with Lynx1 Capital Management LP 8.33% DEF14A
Entities affiliated with Redmile Group, LLC 7.03% DEF14A
Redmile Group, LLC 6.69% 13G
Morgan Stanley 5.70% 13F
Entities affiliated with Morgan Stanley & Co. 5.51% DEF14A

Percentages above are of 62,240,347 shares outstanding, as reported by Stoke Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Stoke Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Stoke Therapeutics, Inc.'s shareholder meeting held 2026-06-03, in the 2025-2026 proxy season, 227 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,407 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — FOR was 73% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Stoke Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.

Stoke Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).